Journal article

Identification of new genetic risk factors for prostate cancer

Michelle Guy, Zsofia Kote-Jarai, Graham G Giles, Ali Amin Al Olama, Sarah K Jugurnauth, Shani Mulholland, Daniel A Leongamornlert, Stephen M Edwards, Jonathan Morrison, Helen I Field, Melissa C Southey, Gianluca Severi, Jenny L Donovan, Freddie C Hamdy, David P Dearnaley, Kenneth R Muir, Charmaine Smith, Melisa Bagnato, Audrey T Ardern-Jones, Amanda L Hall Show all



There is evidence that a substantial part of genetic predisposition to prostate cancer (PCa) may be due to lower penetrance genes which are found by genome-wide association studies. We have recently conducted such a study and seven new regions of the genome linked to PCa risk have been identified. Three of these loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK2/3. The MSMB and KLK2/3 genes may be useful for PCa screening, and the LMTK2 gene might provide a potential therapeutic target. Together with results from other groups, there are now 23 germline genetic variants which have been reported. These results have the potential to be developed into a genetic test. However, we c..

View full abstract


Awarded by Cancer Research UK

Awarded by The National Health and Medical Research Council, Australia

Awarded by Health Technology Assessment Programme

Awarded by Medical Research Council of England

Awarded by USA CDMRP

Awarded by Medical Research Council

Funding Acknowledgements

We should like to thank all the individuals (patients and controls) who took part in our study. Our work is supported by Cancer Research UK Grant C5047/A3354, and by the Biomedical Research Centre at the Institute of Cancer Research and Royal Marsden NHS Foundation Trust. DFE is a Principal Research Fellow of Cancer Research UK. JLH is an Australia Fellow of the NHMRC. We also thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now known as Prostate UK), The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK, The National Health and Medical Research Council, Australia (209057, 251533, 450104), VicHealth, The Cancer Council Victoria, The Whitten Foundation, and Tattersall's. We acknowledge the contribution of all members of the UKGPCS, BAUS and ProtecT study research groups. The ProtecT study is ongoing and is funded by the Health Technology Assessment Programme (projects 96/20/06, 96/20/99). The ProtecT trial and its linked ProMPT and CAP (Comparison Arm for ProtecT) studies are supported by the Department of Health, England; Cancer Research UK grant C522/A8649, Medical Research Council of England grant G0500966, ID 75466 and The NCRI, UK. The epidemiological data for ProtecT were generated though funding from the Southwest National Health Service Research and Development. DNA extraction in ProtecT was supported by the USA CDMRP award number W81XWH-04-1-280. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Department of Health of England.